POS1222 A DISTRICT GENERAL HOSPITAL EXPERIENCE OF BIOLOGIC THERAPY FOR PATIENTS WITH INFLAMMATORY ARTHRITIS AND SPONDYLOARTHROPATHIES

Le résumé fourni par la source

Background: The number of patients on biologic therapies has increased over the past several years and it is important that we are scrutinising the impact of these therapies of patients. Objectives: To investigate the use and corresponding outcomes of biologic treatments used to treat rheumatological conditions. This included patients with Inflammatory arthritis and spondyloarthropathies over a two-year period, at a District General Hospital in the South East of England. Methods: Data was collected from the clinic letters and prescriptions of all patients treated with a biologic agent by the Rheumatology Department throughout the period from January 2022 to January 2024. Those who were on biologic agents for conditions outside of the remit of the Rheumatology Department were excluded. As some patients were trialled on multiple biologic therapies during this period, each biologic therapy they were given was analysed separately. This resulted in the analysis of 2136 biologic treatments. The data collected allowed the exploration of thirteen different biologic agents, examining whether biologic agents were used alongside other therapies, the rate of reported complications and the reported efficacy of their treatment. If patients had their therapy stopped during the audit period, this was recorded as was the therapy the patient was switched onto. Results: Total number of patients: 2136 and 13 biologic agents were included in the project. The practice followed British Society of Rheumatology, NICE and EULAR guidelines for Rheumatoid arthritis, psoriatic arthritis and spondyloarthropahies. Majority of the patients (75%) remained on the same biologic agent for more than 12 months at the time of project. Adverse effects were reported in 14% of treatments. Just above a quarter (28%) of patients required discontinuing the treatment and switched onto another agent either due to adverse effect or inefficacy. Conclusion: The use of biologic agents either as mono therapy or in combination with DMARDs continue to increase significantly at our District General Hospital. All biologic agents were used in compliance with the current guidelines. The study has highlighted the need for a dedicated database of patients on biologic therapies to allow more efficient and real time monitoring of these patients. Future audit should include patients on immunomodulators such as Jak Inhibitors as we increasingly use these agents nowadays. REFERENCES: [1] BSR guidelines for Biologic therapy rheumatoid arthritis, Ankylosing spondylitis and Spondyloarthropathies. [2] NICE guidelines for biologic therapy in rheumatological disorders. [3] EULAR guidelines for Biologic agents in RA and Spondyloarthropathies. Acknowledgements: Dr Verghese Kurien, Dr Mohammed Idrees, Dr Angela Wijeyeratna, Dr Obinna Ezeigwe, Dr Shah Nawaz, Dr Shilpa Renduchintala, Dr Ganira Ahmadova, Dr Sarita Chammanam, Dr Nitin Ramanathan, Dr Aparna Sethi, Dr James Walsh, Dr Louisa Paynter, Dr Rohit Iyyapu, Dr Tania George Dr Ambili Umesh, Dr Anand Anil and Dr Hamza Khattak. Disclosure of Interests: None declared . © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.